GLPwatch
Study of RO6807952 in Patients With Diabetes Mellitus Type 2
NCT01516476 · Terminated
Last updated 2026-05-28This clinical trial tests the safety and effects of the experimental drug RO6807952 in adults with type 2 diabetes.
Status Terminated Stopped early and will not restart.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 2 people
Who can join Ages 18–70 · all sexes
Timeline Started 2011-11 · est. completion 2012-01
Where 1 site · United States
What this study is testing ClinicalTrials.gov NCT01516476 ↗
Description as written by the study sponsor.
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the efficacy and safety of RO6807952 in patients with diabetes mellitus type 2 inadequately controlled with metformin alone. Patients will be randomized to receive doses of RO6807952, placebo, or liraglutide. The anticipated time on study treatment is 12 weeks.
Treatments tested
- Placebo Drug
Placebo for 12 weeks
- RO6807952 Drug
multiple doses for 12 weeks
- RO6807952 Drug
multiple doses for 12 weeks
- liraglutide Drug
liraglutide for 12 weeks
| Main thing measured | Change in hemoglobin A1c (HA1c) |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Conditions studied | Diabetes Mellitus Type 2 |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01516476 ↗